Wednesday, June 20, 2012

FDA panel recommends approval of Onyx myeloma drug

The oncologic drugs advisory committee voted 11-0, with one panel member abstaining, to recommend that the FDA approve Kyprolis. The drug, also known as carfilzomib, is aimed at treating patients with relapsed or refractory multiple myeloma who have received at least two other therapies.
The FDA isn’t required to follow the recommendation of the committee of experts but often does. The agency has until July 27 to make its decision.

No comments:

Post a Comment